281 related articles for article (PubMed ID: 34344966)
1. Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories.
Mizuno S; Yamaguchi R; Hasegawa T; Hayashi S; Fujita M; Zhang F; Koh Y; Lee SY; Yoon SS; Shimizu E; Komura M; Fujimoto A; Nagai M; Kato M; Liang H; Miyano S; Zhang Z; Nakagawa H; Imoto S
Sci Rep; 2021 Aug; 11(1):15713. PubMed ID: 34344966
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
[TBL] [Abstract][Full Text] [Related]
3. Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy.
Xie F; Zhang J; Wang J; Reuben A; Xu W; Yi X; Varn FS; Ye Y; Cheng J; Yu M; Wang Y; Liu Y; Xie M; Du P; Ma K; Ma X; Zhou P; Yang S; Chen Y; Wang G; Xia X; Liao Z; Heymach JV; Wistuba II; Futreal PA; Ye K; Cheng C; Xia T
Clin Cancer Res; 2020 Jun; 26(12):2908-2920. PubMed ID: 31911545
[TBL] [Abstract][Full Text] [Related]
4. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
[TBL] [Abstract][Full Text] [Related]
5. Pan-Cancer HLA Gene-Mediated Tumor Immunogenicity and Immune Evasion.
Gong X; Karchin R
Mol Cancer Res; 2022 Aug; 20(8):1272-1283. PubMed ID: 35533264
[TBL] [Abstract][Full Text] [Related]
6. OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy.
León-Letelier RA; Bonifaz LC; Fuentes-Pananá EM
J Leukoc Biol; 2019 May; 105(5):915-933. PubMed ID: 30698862
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and Immune Silence in Human Cancer.
Yarmarkovich M; Farrel A; Sison A; di Marco M; Raman P; Parris JL; Monos D; Lee H; Stevanovic S; Maris JM
Front Immunol; 2020; 11():69. PubMed ID: 32256484
[TBL] [Abstract][Full Text] [Related]
8. Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape.
Eichmüller SB; Osen W; Mandelboim O; Seliger B
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28383653
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.
Cindy Yang SY; Lien SC; Wang BX; Clouthier DL; Hanna Y; Cirlan I; Zhu K; Bruce JP; El Ghamrasni S; Iafolla MAJ; Oliva M; Hansen AR; Spreafico A; Bedard PL; Lheureux S; Razak A; Speers V; Berman HK; Aleshin A; Haibe-Kains B; Brooks DG; McGaha TL; Butler MO; Bratman SV; Ohashi PS; Siu LL; Pugh TJ
Nat Commun; 2021 Aug; 12(1):5137. PubMed ID: 34446728
[TBL] [Abstract][Full Text] [Related]
10. Immunological-based approaches for cancer therapy.
Barros L; Pretti MA; Chicaybam L; Abdo L; Boroni M; Bonamino MH
Clinics (Sao Paulo); 2018 Aug; 73(suppl 1):e429s. PubMed ID: 30133560
[TBL] [Abstract][Full Text] [Related]
11. [Immunoediting eventually proven in humans. Genetics to assist immunotherapy].
David Fumet J; Ghiringhelli F
Med Sci (Paris); 2019; 35(8-9):629-631. PubMed ID: 31532373
[No Abstract] [Full Text] [Related]
12. SnapShot: Cancer immunoediting.
Varanasi SK; Kaech SM; Bui JD
Cell; 2022 Oct; 185(21):4038-4038.e1. PubMed ID: 36240741
[TBL] [Abstract][Full Text] [Related]
13. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.
Davoli T; Uno H; Wooten EC; Elledge SJ
Science; 2017 Jan; 355(6322):. PubMed ID: 28104840
[TBL] [Abstract][Full Text] [Related]
14. Tackling Resistance to Cancer Immunotherapy: What Do We Know?
Gondhowiardjo SA; Handoko ; Jayalie VF; Apriantoni R; Barata AR; Senoaji F; Utami IJW; Maubere F; Nuryadi E; Giselvania A
Molecules; 2020 Sep; 25(18):. PubMed ID: 32911646
[TBL] [Abstract][Full Text] [Related]
15. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
16. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.
Charoentong P; Finotello F; Angelova M; Mayer C; Efremova M; Rieder D; Hackl H; Trajanoski Z
Cell Rep; 2017 Jan; 18(1):248-262. PubMed ID: 28052254
[TBL] [Abstract][Full Text] [Related]
17. Glutamine Metabolism Regulators Associated with Cancer Development and the Tumor Microenvironment: A Pan-Cancer Multi-Omics Analysis.
Zou J; Du K; Li S; Lu L; Mei J; Lin W; Deng M; Wei W; Guo R
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573287
[TBL] [Abstract][Full Text] [Related]
18. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
19. Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells.
Payne KK; Keim RC; Graham L; Idowu MO; Wan W; Wang XY; Toor AA; Bear HD; Manjili MH
J Leukoc Biol; 2016 Sep; 100(3):625-35. PubMed ID: 26928306
[TBL] [Abstract][Full Text] [Related]
20. Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data.
Hao Y; Li D; Xu Y; Ouyang J; Wang Y; Zhang Y; Li B; Xie L; Qin G
BMC Bioinformatics; 2019 May; 20(Suppl 7):195. PubMed ID: 31074374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
